See every side of every news story
Published loading...Updated

Oruka Therapeutics Announces Preclinical Data for ORKA-002 at the 2025 American Academy of Dermatology Annual Meeting - Pipelinereview

Summary by Pipelinereview
Half-life in non-human primates (NHP) of more than 30 days, over three times longer than bimekizumab and expected to support a dose interval of two to three times per year Equivalent potency to bimekizumab with similar binding affinity and epitope demonstrated in several preclinical assays First subject dosed with ORKA-002 expected in Q3 2025 MENLO PARK, CA, USA I March 07, 2025 I Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-sta…
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

pipelinereview broke the news in on Saturday, March 8, 2025.
Sources are mostly out of (0)

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.